Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,515 signal articles · 49 in last 24h · 122,195 total before filter · latest 1h ago
49last 24h
1259last 7d
213● bullish (7d)
150● bearish (7d)
205publishers
AllMacro210Earnings434M&A97Regulatory23Product9Analyst11
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
IREN (IREN) Is Up 12.3% After Microsoft Accepts Horizon 1 AI Cloud Deployment - What's Changed
Simply Wall St.9d agoneutral
IREN (IREN) Is Up 12.3% After Microsoft Accepts Horizon 1 AI Cloud Deployment - What's Changed

IREN Limited recently confirmed that Horizon 1, the first of four 50MW direct-to-chip liquid-cooled AI cloud deployments, has been delivered to and accepted by Microsoft under their five-year, US$9.70 billion cloud services contract. In parallel, IREN secured NVIDIA Exemplar Cloud status for its GB300 NVL72 deployment at Horizon 1, underscoring its capability to run high-performance AI workloads at scale for hyperscale customers. We’ll now explore how Microsoft’s acceptance of Horizon 1...

How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story
Simply Wall St.9d agoneutral
How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story

In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer’s autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology...

Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs
Simply Wall St.9d agoneutral
Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs

Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk and Eli Lilly medications. These...

Wingstop (WING) Adds PENN CEO To Its Board, Is The Stock Undervalued?
Simply Wall St.9d agoneutral
Wingstop (WING) Adds PENN CEO To Its Board, Is The Stock Undervalued?

Wingstop (WING) shares are in focus after the company expanded its board to eleven members and appointed PENN Entertainment chief executive Jay Snowden as an independent Class II director on August 6, 2026. See our latest analysis for Wingstop. Wingstop’s recent board refresh comes after a tough stretch for shareholders, with the share price down 56.36% year to date and the 1-year total shareholder return declining 67.1%. However, the 1-day share price return of 0.65% hints at some short-term...

Why Fabrinet (FN) Shares Climbed After Its Latest Update
Simply Wall St.9d agoneutral
Why Fabrinet (FN) Shares Climbed After Its Latest Update

Fabrinet (FN) drew fresh attention after announcing that its management will speak at the Rosenblatt 6th Annual Age of AI Technology Summit on August 18, 2026, with investors able to access a live webcast. See our latest analysis for Fabrinet. The recent announcement around Fabrinet's appearance at the AI summit comes as momentum in the stock has picked up again, with a 1 month share price return of 20.49% and a year to date share price return of 19.29%. The 1 year total shareholder return of...

Morgan Stanley doubles down on SpaceX stock for investors
TheStreet9d agoneutral
Morgan Stanley doubles down on SpaceX stock for investors

There is a number making the rounds on Wall Street right now that would have seemed disconnected from reality 12 months ago: a $600 price target for a company that went public at $135 in June and briefly fell below that listing price within weeks of trading. That kind of number does not get ...